|
1
|
Guo XC and Wu YQ: A review: progress of
prevention and control on viral hepatitis in China. Biomed Environ
Sci. 12:227–232. 1999.PubMed/NCBI
|
|
2
|
Ganem D and Prince AM: Hepatitis B virus
infection - natural history and clinical consequences. N Engl J
Med. 350:1118–1129. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thursz M: Genetic susceptibility in
chronic viral hepatitis. Antiviral Res. 52:113–116. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Harnprasopwat R, Ha D, Toyoshima T, Lodish
H, Tojo A and Kotani A: Alteration of processing induced by a
single nucleotide polymorphism in pri-miR-126. Biochem Biophys Res
Commun. 399:117–122. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li J, Yang D, He Y, et al: Associations of
HLA-DP variants with hepatitis B virus infection in southern and
northern Han Chinese populations: a multicenter case-control study.
PLoS One. 6:e242212011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
He XX, Chang Y, Jiang HJ, et al:
Persistent effect of IFNAR-1 genetic polymorphism on the long-term
pathogenesis of chronic HBV infection. Viral Immunol. 23:251–257.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu L, Li J, Yao J, et al: A genome-wide
association study with DNA pooling identifies the variant
rs11866328 in the GRIN2A gene that affects disease progression of
chronic HBV infection. Viral Immunol. 24:397–402. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu L, Yao J, Li J, et al: Effects of
variant rs346473 in ARHGAP24 gene on disease progression of HBV
infection in Han Chinese population. J Huazhong Univ Sci Technolog
Med Sci. 31:482–487. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Szmaragd C, Nichols RA and Balloux F: A
novel approach to characterise pathogen candidate genetic
polymorphisms involved in clinical outcome. Infect Genet Evol.
6:38–45. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ueda H, Howson JM, Esposito L, et al:
Association of the T-cell regulatory gene CTLA4 with susceptibility
to autoimmune disease. Nature. 423:506–511. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carreno BM, Bennett F, Chau TA, et al:
CTLA-4 (CD152) can inhibit T cell activation by two different
mechanisms depending on its level of cell surface expression. J
Immunol. 165:1352–1356. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kuchroo VK, Das MP, Brown JA, et al: B7-1
and B7-2 costimulatory molecules activate differentially the
Th1/Th2 developmental pathways: application to autoimmune disease
therapy. Cell. 80:707–718. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dariavach P, Mattéi MG, Golstein P and
Lefranc MP: Human Ig superfamily CTLA-4 gene: chromosomal
localization and identity of protein sequence between murine and
human CTLA-4 cytoplasmic domains. Eur J Immunol. 18:1901–1905.
1988. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Leach DR, Krummel MF and Allison JP:
Enhancement of antitumor immunity by CTLA-4 blockade. Science.
271:1734–1736. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hellings PW, Vandenberghe P, Kasran A, et
al: Blockade of CTLA-4 enhances allergic sensitization and
eosinophilic airway inflammation in genetically predisposed mice.
Eur J Immunol. 32:585–594. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Karandikar NJ, Vanderlugt CL, Walunas TL,
Miller SD and Bluestone JA: CTLA-4: a negative regulator of
autoimmune disease. J Exp Med. 184:783–788. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kirman J, McCoy K, Hook S, et al: CTLA-4
blockade enhances the immune response induced by mycobacterial
infection but does not lead to increased protection. Infect Immun.
67:3786–3792. 1999.PubMed/NCBI
|
|
18
|
Espenschied J, Lamont J, Longmate J, et
al: CTLA-4 blockade enhances the therapeutic effect of an
attenuated poxvirus vaccine targeting p53 in an established murine
tumor model. J Immunol. 170:3401–3407. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Scheipers P and Reiser H: Fas-independent
death of activated CD4(+) T lymphocytes induced by CTLA-4
crosslinking. Proc Natl Acad Sci U S A. 95:10083–10088. 1998.
|
|
20
|
Ohta A, Sekimoto M, Sato M, et al:
Indispensable role for TNF-alpha and IFN-gamma at the effector
phase of liver injury mediated by Th1 cells specific to hepatitis B
virus surface antigen. J Immunol. 165:956–961. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stoop JN, Woltman AM, Biesta PJ, et al:
Tumor necrosis factor alpha inhibits the suppressive effect of
regulatory T cells on the hepatitis B virus-specific immune
response. Hepatology. 46:699–705. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Han Q, Duan S, Zhang G, et al:
Associations between cytotoxic T lymphocyte-associated antigen-4
polymorphisms and serum tumor necrosis factor-α and interferon-γ
levels in patients with chronic hepatitis B virus infection.
Inflamm Res. 60:1071–1078. 2011.
|
|
23
|
Hu L, Liu J, Chen X, et al: CTLA-4 gene
polymorphism +49 A/G contributes to genetic susceptibility to two
infection-related cancers-hepatocellular carcinoma and cervical
cancer. Hum Immunol. 71:888–891. 2010.
|
|
24
|
Duan S, Zhang G, Han Q, et al: CTLA-4 exon
1 +49 polymorphism alone and in a haplotype with −318 promoter
polymorphism may confer susceptibility to chronic HBV infection in
Chinese Han patients. Mol Biol Rep. 38:5125–5132. 2011.
|
|
25
|
Thio CL, Mosbruger TL, Kaslow RA, et al:
Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B
virus infection. J Virol. 78:11258–11262. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mohammad Alizadeh AH, Hajilooi M, Ranjbar
M, Fallahian F and Mousavi SM: Cytotoxic T-lymphocyte antigen 4
gene polymorphisms and susceptibility to chronic hepatitis B. World
J Gastroenterol. 12:630–635. 2006.PubMed/NCBI
|
|
27
|
Schott E, Witt H, Pascu M, et al:
Association of CTLA4 single nucleotide polymorphisms with viral but
not autoimmune liver disease. Eur J Gastroenterol Hepatol.
19:947–951. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen DQ, Zeng Y, Zhou J, et al:
Association of candidate susceptible loci with chronic infection
with hepatitis B virus in a Chinese population. J Med Virol.
82:371–378. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gu X, Qi P, Zhou F, et al: +49G > A
polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases
susceptibility to hepatitis B-related hepatocellular carcinoma in a
male Chinese population. Hum Immunol. 71:83–87. 2010.
|
|
30
|
Excoffier L and Lischer HE: Arlequin suite
ver 3.5: a new series of programs to perform population genetics
analyses under Linux and Windows. Mol Ecol Resour. 10:564–567.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shevach EM: CD4+
CD25+ suppressor T cells: more questions than answers.
Nat Rev Immunol. 2:389–400. 2002.
|
|
32
|
Fattovich G, Bortolotti F and Donato F:
Natural history of chronic hepatitis B: special emphasis on disease
progression and prognostic factors. J Hepatol. 48:335–352. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang HI, Lu SN, Liaw YF, et al: Hepatitis
B e antigen and the risk of hepatocellular carcinoma. N Engl J Med.
347:168–174. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Aguilar F, Torres B, Sánchez-Román J,
Núñez-Roldán A and González-Escribano MF: CTLA4 polymorphism in
Spanish patients with systemic lupus erythematosus. Hum Immunol.
64:936–940. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Parks CG, Hudson LL, Cooper GS, et al:
CTLA-4 gene polymorphisms and systemic lupus erythematosus in a
population-based study of whites and African-Americans in the
southeastern United States. Lupus. 13:784–791. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Agarwal K, Czaja AJ, Jones DE and
Donaldson PT: Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene
polymorphisms and susceptibility to type 1 autoimmune hepatitis.
Hepatology. 31:49–53. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Agarwal K, Jones DE, Daly AK, et al:
CTLA-4 gene polymorphism confers susceptibility to primary biliary
cirrhosis. J Hepatol. 32:538–541. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Djilali-Saiah I, Ouellette P,
Caillat-Zucman S, Debray D, Kohn JI and Alvarez F: CTLA-4/CD 28
region polymorphisms in children from families with autoimmune
hepatitis. Hum Immunol. 62:1356–1362. 2001. View Article : Google Scholar
|
|
39
|
Fan LY, Tu XQ, Cheng QB, et al: Cytotoxic
T lymphocyte associated antigen-4 gene polymorphisms confer
susceptibility to primary biliary cirrhosis and autoimmune
hepatitis in Chinese population. World J Gastroenterol.
10:3056–3059. 2004.
|
|
40
|
Ahmed S, Ihara K, Kanemitsu S, et al:
Association of CTLA-4 but not CD28 gene polymorphisms with systemic
lupus erythematosus in the Japanese population. Rheumatology
(Oxford). 40:662–667. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ihara K, Ahmed S, Nakao F, et al:
Association studies of CTLA-4, CD28, and ICOS gene polymorphisms
with type 1 diabetes in the Japanese population. Immunogenetics.
53:447–454. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kouki T, Sawai Y, Gardine CA, Fisfalen ME,
Alegre ML and DeGroot LJ: CTLA-4 gene polymorphism at position 49
in exon 1 reduces the inhibitory function of CTLA-4 and contributes
to the pathogenesis of Graves’ disease. J Immunol. 165:6606–6611.
2000.PubMed/NCBI
|
|
43
|
Yee LJ, Perez KA, Tang J, van Leeuwen DJ
and Kaslow RA: Association of CTLA4 polymorphisms with sustained
response to interferon and ribavirin therapy for chronic hepatitis
C virus infection. J Infect Dis. 187:1264–1271. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mäurer M, Loserth S, Kolb-Mäurer A, et al:
A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (
CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics.
54:1–8. 2002.
|
|
45
|
Wang XB, Zhao X, Giscombe R and Lefvert
AK: A CTLA-4 gene polymorphism at position −318 in the promoter
region affects the expression of protein. Genes Immun. 3:233–234.
2002.
|
|
46
|
Ligers A, Teleshova N, Masterman T, Huang
WX and Hillert J: CTLA-4 gene expression is influenced by promoter
and exon 1 polymorphisms. Genes Immun. 2:145–152. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Anjos SM, Tessier MC and Polychronakos C:
Association of the cytotoxic T lymphocyte-associated antigen 4 gene
with type 1 diabetes: evidence for independent effects of two
polymorphisms on the same haplotype block. J Clin Endocrinol Metab.
89:6257–6265. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chistiakov DA, Savost’anov KV, Turakulov
RI, Efremov IA and Demurov LM: Genetic analysis and functional
evaluation of the C/T(−318) and A/G(−1661) polymorphisms of the
CTLA-4 gene in patients affected with Graves’ disease. Clin
Immunol. 118:233–242. 2006.PubMed/NCBI
|
